Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Grupo Español de Investigación en Cáncer de Ovario
Dana-Farber Cancer Institute
Hoffmann-La Roche
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
NeoImmuneTech
Seagen Inc.
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
Varian, a Siemens Healthineers Company
Radiation Therapy Oncology Group
Shattuck Labs, Inc.
Centre Francois Baclesse
I-Mab Biopharma US Limited
Beth Israel Deaconess Medical Center
Merck Sharp & Dohme LLC
Transgene
National Cancer Institute (NCI)
University of Southern California
Wake Forest University Health Sciences
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
University of California, San Diego
Corcept Therapeutics
Merck Sharp & Dohme LLC
New Mexico Cancer Research Alliance
Kaiser Permanente
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Elicio Therapeutics
Institut Bergonié
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Incyte Corporation
Thomas Jefferson University
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Sichuan Enray Pharmaceutical Sciences Company
Merck Sharp & Dohme LLC